Phase 2 study of CP-868,596 + docetaxel, AG-013736 [axitinib] + docetaxel, or CP-868,596 + AG-013736 + docetaxel and of docetaxel alone in patients with stage IIIb or IV non-small cell lung cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2015
At a glance
- Drugs Crenolanib (Primary) ; Axitinib; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 06 Jun 2007 Status changed from initiated to withdrawn prior to recruitment. The study was cancelled before patient enrollment.
- 26 Nov 2006 New trial record.